Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
SABS compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name
SABS
SAB Biotherapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
AMGN
Amgen Inc
Change
Mkt cap
Revenue
Revenue
vs
Compare
SABS
SAB Biotherapeutics, Inc.
vs
AMGN
Amgen Inc
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
SABS
No earnings history for SABS.
AMGN
4 of 4
at or beyond implied
Report
implied
realized
× implied
Q3 FY26
±3.7%
▲
+3.73%
×1.00
Q2 FY26
±4.1%
▲
+4.57%
×1.12
Q1 FY26
±3.9%
▼
−4.75%
×1.23
Feb 4 '26
±3.7%
▲
+8.15%
×2.22
= implied
SABS realized, solid
AMGN realized, hatched
One scale, both sides: full bar = 9%
× = |realized| ÷ implied
Source: market data
SABS
SAB Biotherapeutics, Inc.
Change
3.02
▲
+2.59%
· post 3.02
Mkt cap
$273.0M
Revenue
$114,698
Q4 FY24
Revenue
—
AMGN
Amgen Inc
Change
460.55
▲
+0.06%
· post 460.42
Closed
Nov 6 '26
Mkt cap
$249.0B
Revenue
$10.4B
Q3 FY26
Revenue
$36.8B
FY25
vs
Compare
Closed
Nov 6 '26
SABS
SAB Biotherapeutics, Inc.
vs
AMGN
Amgen Inc
3.02
▲
+2.59%
post 3.02
Price
460.55
▲
+0.06%
post 460.42
$273.0M
Mkt cap
$249.0B
Q4 FY24
$114,698
Revenue
$10.4B
Q3 FY26
—
Revenue
$36.8B
FY25
Change
Change
SABS
3.02
▲
+2.59%
vs
AMGN
460.55
▲
+0.06%
Closed
Nov 6 '26